J
Joshua Betcher
Researcher at Brigham and Women's Hospital
Publications - 7
Citations - 4432
Joshua Betcher is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Edoxaban & Warfarin. The author has an hindex of 5, co-authored 7 publications receiving 3770 citations. Previous affiliations of Joshua Betcher include Quintiles & Research Triangle Park.
Papers
More filters
Journal ArticleDOI
Edoxaban versus warfarin in patients with atrial fibrillation
Robert P. Giugliano,Christian T. Ruff,Eugene Braunwald,Sabina A. Murphy,Stephen D. Wiviott,Jonathan L. Halperin,Albert L. Waldo,Michael D. Ezekowitz,Jeffrey I. Weitz,Witold Rużyłło,Mikhail Ruda,Yukihiro Koretsune,Joshua Betcher,Minggao Shi,Laura T. Grip,Laura T. Grip,Shirali P. Patel,Indravadan Patel,James J. Hanyok,Michele Mercuri,Elliott M. Antman,Elliott M. Antman,Abstr Act,Abstr Act +23 more
TL;DR: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes.
Journal ArticleDOI
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Christian T. Ruff,Robert P. Giugliano,Eugene Braunwald,David A. Morrow,Sabina A. Murphy,Julia F Kuder,Naveen Deenadayalu,Petr Jarolim,Joshua Betcher,Minggao Shi,Karen Brown,Indravadan Patel,Michele Mercuri,Elliott M. Antman +13 more
TL;DR: In this article, higher-dose and lower-dose edoxaban were compared with warfarin in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.
Journal ArticleDOI
Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
Christian T. Ruff,Robert P. Giugliano,Eugene Braunwald,Michele Mercuri,Valentin Curt,Joshua Betcher,Laura T. Grip,Abby Cange,Andrea E. Crompton,Sabina A. Murphy,Naveen Deenadayalu,Elliott M. Antman +11 more
TL;DR: The ENGAGE AF-TIMI 48 transition plan protected patients from an excess of thrombotic and bleeding events and should be helpful in clinical practice when patients are transitioned between oral anticoagulants.
Journal ArticleDOI
Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48
Robert P. Giugliano,Christian T. Ruff,Natalia S. Rost,Scott Silverman,Stephen D. Wiviott,Cheryl Lowe,Naveen Deenadayalu,Sabina A. Murphy,Laura T. Grip,Joshua Betcher,Anil Duggal,Jay Dave,Minggao Shi,Michele Mercuri,Elliott M. Antman,Eugene Braunwald +15 more
TL;DR: In patients with atrial fibrillation, once-daily edoxaban was as effective as warfarin in preventing all strokes, with significant reductions in various subtypes of intracranial bleeding.
Statistical inference under order restrictions in analysis of covariance using a modified restricted maximum likelihood estimator
TL;DR: A new procedure for estimating population parameters under inequality constraints (known as order restrictions) when the unrestricted maximum liklelihood estimator (UMLE) is multivariate normally distributed with a known covariance matrix is introduced.